Inhibition of trigeminal neurones after intravenous administration of naratriptan through an action at 5‐hydroxy‐tryptamine (5‐HT1B/1D) receptors

@article{Goadsby1997InhibitionOT,
  title={Inhibition of trigeminal neurones after intravenous administration of naratriptan through an action at 5‐hydroxy‐tryptamine (5‐HT1B/1D) receptors},
  author={P. J. Goadsby and Yolande E. Knight},
  journal={British Journal of Pharmacology},
  year={1997},
  volume={122}
}
1 The observation that 5‐hydroxytryptamine (5‐HT) is effective in treating acute attacks of migraine when administered intravenously resulted in a research effort that led to the discovery of the 5‐HT1B/1D receptor agonist sumatriptan. 2 Clinical experience has shown sumatriptan to be an effective treatment with some limitations, such as relatively poor bioavailability, which naratriptan was developed to address. Increasing bioavailability has been achieved with greater lipophilicity and thus… Expand
Naratriptan Has a Selective Inhibitory Effect on Trigeminovascular Neurones at Central 5-HT1A and 5-HT1B/1D Receptors in the Cat: Implications for Migraine Therapy
TLDR
Results indicate that naratriptan has a central effect in the trigeminovascular system, selectively inhibiting afferent activity in craniovascular neurones, via both 5-HT1B/1D and 5- HT1A receptors. Expand
Serotonin inhibits trigeminal nucleus activity evoked by craniovascular stimulation through a 5ht 1b/1D receptor: A central action in migraine?
TLDR
Data indicate that 5HT inhibits evoked trigeminal nucleus firing via the 5HT 1B/1D receptor at which GRI127935 is an antagonist, which highlights the case for describing this class of headache as neurovascular headaches rather than vascular headaches, to recognize the implicit contribution of the trigeminovascular system to their pathophysiology. Expand
Comparison of More and Less Lipophilic Serotonin (5HT1B/1D) Agonists in a Model of Trigeminovascular Nociception in Cat
TLDR
This study examined the dorsal horns of the medulla (trigeminal nucleus caudalis) and the C1 and C2 cervical spinal cords in control animals with those receiving zolmitriptan or sumatriptan and noted a significant reduction in Fos expression after treatment with zolMITriptan but no effect with sumatripan. Expand
4991W93, a potent blocker of neurogenic plasma protein extravasation, inhibits trigeminal neurons at 5-hydroxytryptamine (5-HT1B/1D) agonist doses
TLDR
Data suggest that 4991W93 is only effective at modulating the trigeminocervical complex at 5-HT(1B/1D) agonist doses, to account for neurogenic dural plasma protein extravasation blockade in animal studies. Expand
Differential effects of low dose CP122,288 and eletriptan on Fos expression due to stimulation of the superior sagittal sinus in cat☆
TLDR
The data suggest that activation of the 5HT(1B/1D) receptor is important for the clinical action of this class of compounds and is consistent with the fact the CP122,288 is ineffective in the treatment of the acute attack of migraine. Expand
The antimigraine 5‐HT1B/1D receptor agonists, sumatriptan, zolmitriptan and dihydroergotamine, attenuate pain‐related behaviour in a rat model of trigeminal neuropathic pain
TLDR
The rationale for exploring the clinical efficacy of brain penetrant 5‐HT1B/1D receptor agonists as analgesics to reduce certain types of trigeminal neuropathic pain in humans is supported. Expand
Activation of 5‐HT1B/1D receptor in the periaqueductal gray inhibits nociception
TLDR
The results suggest that 5‐HT1B/1D receptor activation in the vlPAG activates descending pain‐modulating pathways that inhibit dural, but not facial and corneal nociceptive input, suggesting that brain loci other than the trigeminal nucleus may play a role in the clinical action of triptans. Expand
The effects of 5-HT1A, 5-HT1B and 5-HT1D receptor agonists on trigeminal nociceptive neurotransmission in anaesthetized rats.
TLDR
In anaesthetized rats, the 5-HT1B/1D receptor agonist, zolmitriptan, inhibited the action potential discharge of single trigeminal neurones to noxious electrical stimulation of the middle meningeal artery. Expand
Serotonin Infusions Inhibit Sensory Input From the Dural Vasculature
TLDR
The results suggest that earlier clinical observations that 5HT infusions can ameliorate the pain of migraine may not have been due to cranial vasoconstriction alone, but could have involved a central action of 5HT. Expand
The role of 5-HT1B and 5-HT1D receptors in the selective inhibitory effect of naratriptan on trigeminovascular neurons
TLDR
The results suggest that the response of nucleus caudalis neurons to stimulation of the sagittal sinus can be modulated by both 5- HT(1B) and 5-HT(1D) receptor activation, with the 5-ht( 1D) receptors perhaps playing a greater role. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 64 REFERENCES
Inhibition of trigeminal neurons by intravenous administration of the serotonin (5HT)1B/D receptor agonist zolmitriptan (311C90): are brain stem sites therapeutic target in migraine ?
TLDR
It is demonstrated that systemically administered zolmitriptan can inhibit evoked trigeminovascular activity within the trigeminal nucleus, which may play a role in the anti‐migraine actions of this compound and offers the prospect of a third pathophysiologically consistent target site for anti‐Migraine drug effects. Expand
Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine. A c-Fos and electrophysiological study.
TLDR
Together, these studies show that DHE can inhibit activity in central trigeminal neurons, implying that drugs acting at the central trigEMinal neurons may have a role in the treatment of acute attacks of migraine. Expand
Direct Evidence for Central Sites of Action of Zolmitriptan (311C90)
TLDR
Ex vivo and in vitro data confirm the existence of a population of receptors that specifically bind zolmitriptan following systemic administration and reinforce the importance of central trigeminal neurons as a possible site of action of anti-migraine drugs. Expand
Inhibition by sumatriptan of central trigeminal neurones only after blood‐brain barrier disruption
TLDR
The data suggest that in normal circumstances sumatriptan does not have sufficient access to trigeminal neurones to alter their function, and that the blood‐brain barrier is normal or abnormal during a migraine attack. Expand
Comparison of the effects of sumatriptan and the NK1 antagonist CP-99,994 on plasma extravasation in dura mater and c-fos mRNA expression in trigeminal nucleus caudalis of rats
TLDR
The results suggest that brain penetrant NK1 receptor antagonists may have anti-migraine effects peripherally through blockade of dural extravasation and centrally by inhibition of nociceptive pathways. Expand
Preclinical studies on the anti-migraine drug, sumatriptan.
TLDR
The passage of sumatriptan and its metabolites across the blood-brain barrier appeared to be very limited, although some drug could be detected in the cerebrospinal fluid after administration of high intravenous doses. Expand
Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels.
TLDR
The data point to a preferential expression of 5-HT1Dalpha receptors in neural versus vascular tissues and strongly reemphasize the need for selective 5- HT1D alpha agonists in the identification of the target tissue(s) for antimigraine drugs. Expand
Rizatriptan has central antinociceptive effects against durally evoked responses.
TLDR
Rizatriptan has central activity which may contribute to its efficacy against migraine headache and may also have activity at 5-HT(1B/1D) receptors within the central nervous system (CNS) that contributes to its antimigraine effects. Expand
Localization of 3H‐Dihydroergotamine‐binding sites in the cat central nervous system: Relevance to migraine
TLDR
Using in vitro and ex vivo autoradiographic techniques, the localization of specific binding sites for 3H‐dihydroergotamine in the cat brain has been examined, finding the highest density of binding sites was found in the dorsal and medial raphe nuclei of the midbrain. Expand
Extracellular Recordings of Membrane Potential from Guinea-Pig Isolated Trigeminal Ganglion: Lack of Effect of Sumatriptan
TLDR
The data provide no evidence to suggest that sumatriptan inhibits neurotransmission in trigeminal ganglion, however, 5-HT1 receptors may be present in insufficient numbers in the trigeminals to elicit a change in membrane potential. Expand
...
1
2
3
4
5
...